About Encruso
Nano Therapeutics is the first company in India to develop and launch Everolimus Eluting Coronary Stent System (Encruso)<br /> Encruso, offers a stent with unmatched surface finish. With its ultra-thin strut thickness, Encruso stent provides increased flexibility, reduced profile, improved trackability, and faster endothelialization, while its high resistance against arterial pressure and radial force ensures no structural deformation during overexpansion.
Get in touch
Unlock New Possibilities for Coronary Intervention with Encruso
Contact Us Today
Contact us today to discover the cutting-edge advancements and exceptional outcomes that Encruso offers in the field of cardiovascular care.